GTCB: IO, the pps is probably being supported by new investors who bought on the media hype. These same folks do not seem to know that GTCB will not have an approval anytime soon. They are only looking at the "low" pps and the prospects for a "review" by the EMEA, and the misguided expectation of a FDA decision in the near future. ("review" is not my phrase)
"Illegitimacy is something we should talk about in terms of not having it."